Prostatic occurrence of transitional cellcarcinoma after intravesical chemotherapy

Michael J. Lemmers, Eugene Fuchs, Thomas R. Hatch, Bruce A. Lowe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thirteen patients with Stage Tis, Ta, or T1 transitional cell carcinoma (TCC) of thebladder treated by transurethral resections and intravesical chemotherapy developed TCC of the prostate. Among the 13 cases, cytology specimens were obtained from 10 at the time prostatic disease was diagnosed; 9 demonstrated TCC. One was treated successfully by transurethral resection of a Ta lesion involving the prostatic urethra only. One of 2 patients declining radical surgery is alive with residual disease at twenty-four months, and the other died of progressive disease at nineteen months. Of the 10 patients who underwent radical eystoprostatectomy, 7 are alive with no evidence of disease eight to forty-two months postoperatively, with 2 of these 7 having received 4 courses of systemic methotrexate, vincristine, Adriamyein, and cisplatinum (MVAC) for metastatic disease. Two of the 10 died of metastatie disease six and thirteen months postoperatively, and one frail patient died of surgical complications. When treating patients with intravesical chemotherapy for superficial TCC, biopsy of the prostate should be done during follow-up examinations, especially in the presence of cytologic or palpable prostatic abnormalities.

Original languageEnglish (US)
Pages (from-to)423-427
Number of pages5
JournalUrology
Volume37
Issue number5
DOIs
StatePublished - 1991

Fingerprint

Transitional Cell Carcinoma
Drug Therapy
Prostate
Prostatic Diseases
Vincristine
Urethra
Methotrexate
Cell Biology
Biopsy

ASJC Scopus subject areas

  • Urology

Cite this

Prostatic occurrence of transitional cellcarcinoma after intravesical chemotherapy. / Lemmers, Michael J.; Fuchs, Eugene; Hatch, Thomas R.; Lowe, Bruce A.

In: Urology, Vol. 37, No. 5, 1991, p. 423-427.

Research output: Contribution to journalArticle

Lemmers, Michael J. ; Fuchs, Eugene ; Hatch, Thomas R. ; Lowe, Bruce A. / Prostatic occurrence of transitional cellcarcinoma after intravesical chemotherapy. In: Urology. 1991 ; Vol. 37, No. 5. pp. 423-427.
@article{48cf9fc98623496ca8d6c941c06a598c,
title = "Prostatic occurrence of transitional cellcarcinoma after intravesical chemotherapy",
abstract = "Thirteen patients with Stage Tis, Ta, or T1 transitional cell carcinoma (TCC) of thebladder treated by transurethral resections and intravesical chemotherapy developed TCC of the prostate. Among the 13 cases, cytology specimens were obtained from 10 at the time prostatic disease was diagnosed; 9 demonstrated TCC. One was treated successfully by transurethral resection of a Ta lesion involving the prostatic urethra only. One of 2 patients declining radical surgery is alive with residual disease at twenty-four months, and the other died of progressive disease at nineteen months. Of the 10 patients who underwent radical eystoprostatectomy, 7 are alive with no evidence of disease eight to forty-two months postoperatively, with 2 of these 7 having received 4 courses of systemic methotrexate, vincristine, Adriamyein, and cisplatinum (MVAC) for metastatic disease. Two of the 10 died of metastatie disease six and thirteen months postoperatively, and one frail patient died of surgical complications. When treating patients with intravesical chemotherapy for superficial TCC, biopsy of the prostate should be done during follow-up examinations, especially in the presence of cytologic or palpable prostatic abnormalities.",
author = "Lemmers, {Michael J.} and Eugene Fuchs and Hatch, {Thomas R.} and Lowe, {Bruce A.}",
year = "1991",
doi = "10.1016/0090-4295(91)80102-D",
language = "English (US)",
volume = "37",
pages = "423--427",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prostatic occurrence of transitional cellcarcinoma after intravesical chemotherapy

AU - Lemmers, Michael J.

AU - Fuchs, Eugene

AU - Hatch, Thomas R.

AU - Lowe, Bruce A.

PY - 1991

Y1 - 1991

N2 - Thirteen patients with Stage Tis, Ta, or T1 transitional cell carcinoma (TCC) of thebladder treated by transurethral resections and intravesical chemotherapy developed TCC of the prostate. Among the 13 cases, cytology specimens were obtained from 10 at the time prostatic disease was diagnosed; 9 demonstrated TCC. One was treated successfully by transurethral resection of a Ta lesion involving the prostatic urethra only. One of 2 patients declining radical surgery is alive with residual disease at twenty-four months, and the other died of progressive disease at nineteen months. Of the 10 patients who underwent radical eystoprostatectomy, 7 are alive with no evidence of disease eight to forty-two months postoperatively, with 2 of these 7 having received 4 courses of systemic methotrexate, vincristine, Adriamyein, and cisplatinum (MVAC) for metastatic disease. Two of the 10 died of metastatie disease six and thirteen months postoperatively, and one frail patient died of surgical complications. When treating patients with intravesical chemotherapy for superficial TCC, biopsy of the prostate should be done during follow-up examinations, especially in the presence of cytologic or palpable prostatic abnormalities.

AB - Thirteen patients with Stage Tis, Ta, or T1 transitional cell carcinoma (TCC) of thebladder treated by transurethral resections and intravesical chemotherapy developed TCC of the prostate. Among the 13 cases, cytology specimens were obtained from 10 at the time prostatic disease was diagnosed; 9 demonstrated TCC. One was treated successfully by transurethral resection of a Ta lesion involving the prostatic urethra only. One of 2 patients declining radical surgery is alive with residual disease at twenty-four months, and the other died of progressive disease at nineteen months. Of the 10 patients who underwent radical eystoprostatectomy, 7 are alive with no evidence of disease eight to forty-two months postoperatively, with 2 of these 7 having received 4 courses of systemic methotrexate, vincristine, Adriamyein, and cisplatinum (MVAC) for metastatic disease. Two of the 10 died of metastatie disease six and thirteen months postoperatively, and one frail patient died of surgical complications. When treating patients with intravesical chemotherapy for superficial TCC, biopsy of the prostate should be done during follow-up examinations, especially in the presence of cytologic or palpable prostatic abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=0025758373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025758373&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(91)80102-D

DO - 10.1016/0090-4295(91)80102-D

M3 - Article

C2 - 2024389

AN - SCOPUS:0025758373

VL - 37

SP - 423

EP - 427

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -